Microbiotica Limited news

Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has received project funding from the Crohn’s & Colitis Foundation, as part of their IBD Ventures program, for the development of therapies to treat inflammatory bowel disease (IBD). The project, to support the ongoing development of Microbiotica’s Live Bacterial Therapeutic (LBT) MB310 for the treatment of ulcerative colitis (UC), was funded following an extensive review process

Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series B financing round – the largest microbiome-related financing in Europe to date.

The international investment syndicate was co-led by Flerie Invest, a major Swedish life science investor focussing on companies with ambitious science and the ability to tackle major medical challenges, and Tencent, a gl

Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces that MB097 is now in pre-clinical development for treatment of patients not responding to anti-PD1 therapy. Clinical trials are due to begin in 2022. MB097 is clinically designed and experimentally validated.

Studies have shown that the gut microbiome plays a critical and causative role in determining which cancer patients respond to Immune Checkpoint Inhibitor (ICI) therapy. However clinic

• MB097 is a consortium of bacteria at the core of the microbiome signature predictive of patient response to Immune Checkpoint Inhibitor therapy
• Data show potent anti-tumour efficacy in vivo and in vitro
• MB097 is in manufacturing process development for Ph1b study expected to start next year
• MB097 is the first microbiome precision medicine in immuno-oncology, clinically designed in the same patient cohort in which it will be tested

&

Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, has been highly commended in the “Life Science Company of the Year” category at the 4th Cambridge Independent Science and Technology Awards.

The Company was recognised for its transformational technology and significant progress over the past year. Recent achievements include a key new strategic collaboration with Cancer Research UK and Cambridge University Hospitals, progressing lead programme

Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces the appointment of Hans Schikan as Non-Executive Chairman, effective immediately.

Hans brings decades of commercial, development, transactional and leadership experience from the biopharma industry. He is a well-established biopharma leader, having held many board memberships on both private and publicly listed companies throughout his career, and currently serves on the boards of Pharvaris NV, V

Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces the appointment of Ronald Carter, MD, as Chief Medical Officer (CMO), and the appointment of Tim Sharpington as Chief Operating Officer (COO).

Ron Carter joins the Company as CMO at an important stage of its development, with major development programmes currently underway in Immuno-oncology and IBD. He will be responsible for progressing the clinical development of the Company’s Live

Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, been selected as a finalist in the ‘Best Emerging Biotech Company’ category at the OBN Awards 2020. The winners will be announced on Thursday 26th November.

Microbiotica has established itself as a leading global player in its field, and most recently it has been recognised for its collaboration with Cancer Research UK and CUH. This has so far allowed the company to discover the first gut bacte